Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
CRM
IHD
KJX839 - siRNA (regulation of LDL-C)
Study
Indication
Phase
Patients
Primary Outcome
Measures
NCT04652726 ORION-16 (CKJX839C12301)
Hyperlipidemia, pediatrics
Phase 3
150
Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline
to Day 330
Arms Intervention
NCT04659863 ORION-13 (CKJX839C12302)
Hyperlipidemia, pediatrics
Phase 3
15
Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline
to day 330
Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360,
inclisiran sodium 300mg on Days 450 and 630;
Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450
and 630.
Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360,
inclisiran sodium 300mg on Days 450 and 630;
Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450
and 630.
Adolescents (12 to less than 18 years) with heterozygous familial
hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-
Adolescents (12 to less than 18 years) with homozygous familial
hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-
Target Patients
C)
Read-out Milesstone(s)
Publication
2023
TBD
63 Investor Relations | Q2 2021 Results
2023
TBD
1 NOVARTIS | Reimagining MedicineView entire presentation